Abstract： Objective： To observe the clinical effect of the additional application of Shugan Jieyu Capsules combined with Escitalopram Oxalate based on routine treatment for post-stroke depression with liver constraint and spleen deficiency syndrome. Methods：A total of 132 cases of patients with post-stroke depression with liver constraint and spleen deficiency syndrome were selected as the study subjects，and divided into the control group and the study group according to the random number table method， with 66 cases in each group. Both groups were treated with routine treatment and Escitalopram Oxalate Tablets， and the study group was additionally treated with Shugan Jieyu Capsules. Both groups were treated for consecutive 12 weeks. Before treatment and after 12-week treatment，the depression degree was evaluated by Hamilton Rating Scale for Depression(HAMD- 24) scores，the neurologic impairment by National Institutes of Health Stroke Scale(NIHSS) scores， the cognitive function by Mini- Mental State Examination(MMSE) scores，and the ability of daily living by Barthel Index(BI) scores；the levels of tumor necrosis factor-α(TNF-α)，interleukin-1β(IL-1β) and 5-hydroxytryptamine(5-HT) in serum were detected. During the 12- week treatment ， the incidence of adverse reactions of patients was counted. After 12- week treatment， the curative effects of depression improvement and traditional Chinese medicine syndromes were evaluated. Results：After 12-week treatment，the total effective rates of curative effects of depression improvement and Chinese medicine syndromes in the study group were higher than those in the control group，differences being significant(P＜0.01). The scores of HAMD- 24 and NIHSS in the two groups were decreased when compared with those before treatment， and the scores of MMSE and BI were increased，differences being significant(P＜0.01)；the scores of HAMD- 24 and NIHSS in the study group were lower and the scores of MMSE and BI were higher than those in the control group，differences being significant(P＜0.01). The levels of TNF-α and IL-1β in serum in the two groups were decreased when compared with those before treatment， and the 5- HT levels were increased(P＜0.01)； the levels of TNF- α and IL-1β in serum in the study group were lower and the 5-HT level was higher than those in the control group，the difference being significant(P＜0.01). There being no significant difference being found in the comparison of the incidence of adverse reactions between the two groups(P＞0.05). Conclusion： Based on routine treatment， the additional application of Shugan Jieyu Capsules combined with Escitalopram Oxalate for post- stroke depression with liver constraint and spleen deficiency syndrome can effectively improve clinical effects，symptoms，cognitive function and ability of daily living，reduce degree of neurological damage， promote the improvement of neuroendocrine function， relieve depression degree，and inhibit neuroinflammation with high treatment safety.